A major goal of Neuroscape is the translation of the research findings that emerge from our Neuroscience Division, as driven by the advances of our Technology Division, to the creation of new clinical diagnostic tools and therapeutic interventions that better the lives of diverse patient populations.
The Neuroscape Clinical Division was born out of our dissatisfaction with the present approach to treating cognitive deficits in neurological and psychiatric patients. The current system is overly reliant on antiquated assessments, poorly-targeted drugs and non-personalized prescriptive practices. Silos constructed around each treatment modality have further prevented much needed breakthroughs.
Through unique collaborations between the Neuroscape Core team, physician-scientists both within and outside of UCSF, and select industry partners we extend the progress of our other divisions to positively impact brain function of individuals suffering from multiple clinical conditions. These efforts also include improvements in experimental design, notably double-blinded, randomized, placebo-controlled studies of non-invasive technologies.
The Clinical Division currently targets the following conditions: Attention Deficit/ Hyperactivity Disorder (ADHD), Autism, Mild Cognitive Impairment and Dementia, Depression, and Traumatic Brain Injury (TBI). New research focus areas of Multiple Sclerosis, Delirium, Sensory Processing Disorder and Cancer-related Cognitive Impairment (CRCI) will be launching soon
Joaquin A. Anguera
Director, Clinical Division